Most recently, in August 2022, FDA approved ADC trastuzumab deruxtecan, which is a trastuzumab linked deruxtecan chemo agent, for the treatment of patients with unresectable or metastatic HER2-low breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.